Phase III sofosbuvir data overshadow strong Gilead sales growth
This article was originally published in Scrip
Executive Summary
Gilead Sciences delivered impressive fourth quarter and year-end 2012 revenue totals driven by the Foster City, California-based company's market-leading HIV franchise, but almost all that analysts wanted to talk about during Gilead's afternoon earnings call was Phase III results for the company's hepatitis C virus (HCV) therapy sofosbuvir.